Background: There have been several reports that statin therapy is associated with a slightly higher incidence of new-onset diabetes mellitus(DM) or impaired glucose intolerance(IGT). It is still controversial whether the chronic statin therapy is a risk factor of IGT and new onset DM, in Asian population. Methods: We investigated the 13,561 patients(pts) that was HbA1c level Ͻ6.0% and fasting glucose level Ͻ124 mg/dL(statin therapy groupϭ4016 and control groupϭ9545). To adjust potential confounders including age, gender, hypertension, hyperlipidemia, chronic kidney disease, hyper/hypo-thyroidism, lipid profile, beta-blocker, diuretics, a propensity score matched analysis was performed using the logistic regression model. The primary end-point was the cumulative incidence of new-onset DM, IGT, and impaired fasting glucose(IFG). Also, Multivariable Cox-regression analysis adjusted aforementioned variables was performed to determine the impact of statin therapy on the incidence of new-onset DM, IGT, and IFG. Results: Mean follow-up duration was 534Ϯ604 days in all group, and 608Ϯ607 days in propensity score matching group. Baseline characteristics was similar between the two groups except hyperlipidemia (11.1% vs. 3.5%, pϽ0.001). In Kaplan-Meyer curve, there was no difference between the two groups (pϭ0.501, figure A) . Also, in cox-regression analysis performed in all pts, statin therapy was not associated with the increased incidence of primary end-point(figure B). Conclusions: In our study, there was no clear association with statin therapy and IGT and new-onset DM in a series of cardiovascular pts in Asian population. 
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Background: Introduction Few data is available on the comparison between diabetic and non-diabetic patients after percutaneous coronary intervention (PCI) with drug eluting stents for unprotected left main coronary artery disease. Hypothesis We assessed the hypothesis that diabetes mellitus is a predictor of worse clinical outcome after PCI with drug eluting stents for unprotected left main disease. Methods: This is a multicenter registry enrolling consecutive patients undergoing PCI with paclitaxel or everolimus-eluting stents for unprotected left main disease. Death, cardiac death, myocardial infarction (MI), clinically-driven-target lesion revascularization (TLR), target vessel revascularization (TVR), stroke, definite/probable stent thrombosis were assessed at 2-year follow-up. A multiple cox regression analysis was performed. Hazard ratios (HR) with 95% confidence interval (CI) were calculated. Results: A total of 331 patients, median age 71 yrs-old, (25th-75th percentile 62-78), 87 (26.3%) diabetics, 172 undergoing paclitaxel eluting stent and 159 undergoing everolimus eluting stent implantation, were enrolled. At 2-year follow-up diabetics, as compared to non-diabetic patients, presented a higher incidence of death (14.9% vs 4.5%, pϭ0.001), cardiac death (9.2% vs 2.9%, pϭ0.015), stroke (5.7% vs 0.8%, pϭ0.015), definite/probable stent thrombosis (3.4% vs 0%, pϭ0.018), the composite of death/MI/stroke, (21.8% vs 9.8%, pϭ0.004), the composite of death/MI/TLR (22.9% vs 13.1%, pϭ0.03), and the composite of death/MI/TLR/stroke (25.3% vs 13.5%). No significant differences between diabetics and non-diabetic patients were found with respect to MI (10.3% vs 6.1%, pϭ0.19) Background: Plain Old Balloon Angioplasty (POBA) for In-Stent Restenosis (ISR) in the superficial femoral artery (SFA) and proximal popliteal artery (PA) has a recurrent stenosis rate of up to 70% within 12 months. Aim of the study was to test the ability to reduce this high recurrency rate with a Paclitaxel Eluting Balloon (PEB). Methods: Since January 2010, 44 consecutive patients with symptomatic in-stent restenosis of the SFA or proximal PA were treated with PEB (Admiral In.Pact, Medtronic, Minnesota, USA). The occurrence of re-restenosis and repeat intervention at 1-year follow up was compared to those of 42 consecutive patients treated with POBA from January 2008 to December 2009. Results: No significant difference in terms of clinical, angiographic and procedural characteristics were observed among the two study groups. Respectively: Age 74Ϯ11 in PEB vs 76Ϯ7 in POBA, Pϭ0.1; insuline therapy 23/44(50%) vs 21/42(48%), pϭ0.9; Rutherford ClassՆ4 33/44(75%) vs 28/42(67%), pϭ0.8; serum creatinine 1.09Ϯ1.5mg/dL vs 1.02Ϯ1.5mg/dL, pϭ0.9; occlusive ISR 23/44(52%) vs 28/42(66%), pϭ0.1; restenosis length 131Ϯ86mm vs 138Ϯ85mm, pϭ0.4. Procedural success, defined as a residual stenosis Ͼ 30% in the restenotic segment (stentϩ5mm of proximal and distal edges), was obtained in all treated lesions and no adverse clinical events occurred during hospitalization in both groups. At one-year follow-up, 6 patients died (3 in PEB and 3 in POBA), one patient in POBA group underwent major amputation. Restenosis, assessed by angiography or ultrasound, occurred in 8/41(19%) PEB vs 28/39(72%) POBA, pϽ0.05. Repeat angioplasty for symptomatic in stent re-restenosis occurred in 6/44(13%) PEB vs 13/42(31%) POBA, pϽ0.05. Conclusions: Repeat balloon angioplasty for ISR in the SFA and proximal PA artery using PEB showed a significant reduction in re-restenosis and repeat angioplasty compared to POBA at 1-year follow-up. Background: Diabetic patients (DP) show more complex coronary artery disease than non-diabetic patients (N-DP) and diabetes mellitus (DM) predicts adverse outcome after MI. We sought to investigate the interaction of reperfusion and DM on mortality after STEMI treated with primary PCI. Methods: A multicenter registry of consecutive patients treated with primary PCI in 3 centers. Vital status was obtained through municipality records. Reperfusion was scored by TIMI flow. Cox regression was used to analyze effect modification of the correlation between sub-optimal reperfusion (TIMIϾ3) and mortality by DM. Results: In total, 386 DP and 3063 N-DP were treated with primary PCI. DP were older (66.7 vs. 62.8 years in N-DP, pϽ0.001), less often male (68.4% vs. 75.9% in N-DP, pϭ0.001), more frequently suffered a previous MI (14.3% in DP vs. 10.3% N-DP, pϭ0.018) and renal insufficiency (12.5% vs. 2.6% in N-DP, pϽ0.001). Moreover, DP showed more multi-vessel disease (31.3% vs. 20.3% in N-DP, pϽ0.001). TIMI flow before and after PCI was similar. Mortality was higher in DP (30 day: 9.1% vs. 3.8% in N-DP, pϽ0.001, 1 year: 14.5% in DP vs. 6.1% in N-DP, pϽ0.001). Furthermore, DP patients showed substantially worse 1 year mortality after sub-optimal reperfusion compared to N-DP (figure), an interaction which was confirmed by cox regression (interaction HR 2.36, 95% CI 1.11-5.03 after correction for confounders). 
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